Bragar Eagel & Squire, P.C. is investigating Qiagen N.V. on behalf of its stockholders following a significant stock price drop of about 11% after the company reported a 5% decline in sales of its QuantiFERON product in Q1 2026, contradicting earlier growth expectations. The investigation focuses on whether Qiagen violated federal securities laws or engaged in unlawful business practices. Investors who suffered losses or have information are encouraged to contact the law firm to discuss their legal options. This could lead to potential legal action if wrongdoing is found.
A newly created crypto wallet placed a $2.25 million, 10x leveraged long bet on 20 million Dogecoin (DOGE), signaling strong confidence in a price rise. This leveraged position has a liquidation price just under 10% below the current DOGE price, mean...
Greg Brockman, co-founder and president of OpenAI, is now officially leading the company's product strategy, stepping in during CEO Fidji Simo's medical leave. He plans to unify ChatGPT and Codex into a single product experience, focusing on both con...
Netflix's ad-supported subscription tier has grown to over 250 million monthly active viewers worldwide, a massive increase from 70 million in 2024. This audience size rivals the population of Brazil, making advertising a major revenue driver for the...
Klarna reported strong Q1 2026 results, with revenue reaching $1.012 billion, up 44% year-over-year, surpassing estimates by $68.13 million. The company also improved its transaction margin by 44% to $389 million and turned net income positive, repor...
Ripple has secured ten major bank partnerships in 2026, including Deutsche Bank and JPMorgan, but XRP's price has dropped 41% since January. The reason is that most deals use Ripple's stablecoin RLUSD for settlements, which doesn't require XRP, limit...
